Circulating tumour cells in patients with lung cancer universally indicate poor prognosis.
Journal Information
Full Title: Eur Respir Rev
Abbreviation: Eur Respir Rev
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest: S. Loges reports grants and personal fees from BerGenBio AS, BMS, and Roche, and personal fees from Lilly, Sanofi, Novartis, Boehringer Ingelheim, AstraZeneca, MSD, Sanofi Aventis, Janssen, Takeda and Daiichi-Sankyo outside the submitted work. The other authors reported no disclosures."
"Support statement: This work is supported by the China Scholarship Council (CSC) (L. Zhu, no. 201908080072; F. Jin, no. 202208080138); and Hector Stiftung II (S. Loges and S. Schölch). No sponsor had any role in the study design, data collection, analysis, interpretation, the writing, and decision to submit the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025